Zaks Tal Zvi 4

What Happened

• Tal Zaks, a director of Teva Pharmaceutical Industries Ltd. (TEVA), had restricted share units (RSUs) convert/exercise on June 5, 2026. The filing shows 14,492 shares were acquired on conversion and the same 14,492 shares were recorded as disposed at $0.00.
• No cash value is reported for the disposed shares (total reported value $0). The filing identifies these as derivative transactions (code M), reflecting conversion/exercise of equity awards rather than an open‑market buy or sale.

Key Details

• Transaction date: 2026-06-05. Filing date: 2026-06-08. No late filing is indicated in the report.
• Acquired: 14,492 ordinary shares on conversion (price: N/A). Disposed: 14,492 shares at $0.00 (reported value $0).
• Shares owned after transaction: Not reported in the filing.
• Footnotes: F1 — Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 ordinary share). F2 — Each RSU represents a contingent right to one ordinary share or cash at the committee’s option. F3 — These RSUs were granted June 5, 2025 and vested June 5, 2026.
• Transaction code: M (exercise or conversion of a derivative/award).

Context

• This was a conversion/settlement of RSUs that vested on June 5, 2026. Conversions of RSUs produce shares to the insider; the reported disposal at $0.00 typically reflects a net settlement or share withholding for taxes or administrative obligations rather than an open‑market sale.
• These entries are about award settlement mechanics and do not necessarily signal a directional bet by the director (they are not an open‑market purchase or sale).